Emerging targets like H3K79me1/2/3 (DOT1L inhibitors) and H3K9me2 (G9a/EHMT2 inhibitors) are showing potential in preclinical studies of breast cancer [15,16,17]. This evidence concerns the gene EHMT2 and breast cancer.